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ABSTRACT
In this paper a review of the role brachytherapy in the treatment of vulvar cancer is presented.
Although external beam irradiation has been the most commonly method used in patients with vulvar
malignancies not suitable for surgery, there has been increasing interest in using brachytherapy
instead of or combined with teletherapy. Issues such as patients selection, interstitial techniques,
integration with other local therapies and complications are highlighed.
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Carcinoma of the vulva accounts for 2.5 - 4.0%
of all gynecological neoplasms. The incidence in
Poland is 1-2 per 100 000 women with tendency
of increasing rates in older age (Tarfowska
1983). Traditionally, the standard treatment for
invasive carcinoma of the vulva has been
radical vulvectomy with bilateral inguinal lymph
node dissection. Radiation therapy has for long
been considered to have a limited role in
primary management of vulvar cancer because
of the belief that the vulva and perineal tissues
tolerate radiation therapy poorly. Also, the
results of radiotherapy alone as primary
treatment seems to be inferior to surgical
methods. That was mainly caused by selection
of patients treated by irradiation with poor
prognostic features (Miecznikowski 1993).
Primary radiotherapy has been often used in
cases with fixed tumors positive inguinal or in
frail patients. The advent of megavoltage
external beam equipment, integration of external
beam and brachytherapy and individualization
with good treatment planning have improved
tolerance of radiotherapy and are essential to
achieve a better cure rate. The reappraisal of
radiotherapy has led to new strategies for
earlydisease using less radical surgery in
combination with radiotherapy with preservation
of function and cosmesis in the treatment of
vulvar malignancies. Also, for advanced vulvar
carcinomas the radiotherapy may be a
reasonable alternative to exenteration (Snijders-
Keilholz 1993). The aim of is study was a short
review of eight decades of brachytherapy in the
treatment of the carcinoma of the vulva.
Intersitial implantation in the treatment
of vulvar malignancies were used as early as
1914. Radon 222 with a half-life of 3.82 days
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was the first radioisotope used for permament
implants (cit. Erickson 1996). The glass seeds
of radon were manualy implanted in the vulvar
and perineal tissues. This procedure was
subsequently abandoned becouse of the painful
reactions that developed at the implantation
place from the emitted beta rays and poor five
year survival. In the 1920 gold filtered radon
seeds with minimal beta rays emission were
introduced and replaced the glass seeds (Perez
1992). In the following years this procedure,
often combined with external beam irradiation,
has been used in the treatment of vulvar cancer
usually with palliative intent. The sources were
inserted in and around the tumor to give a dose
of 100 mCi/hr. A wide variety of encapsulated
radioactive sources have been used in
brachytherapy of the vulvar cancer since first
clinical applications of radon seeds.
Radium needles containing radium sulfate with
filler (barium sulfate) replace radon seeds.
Needles with 1.0 mg Ra/cm or 0.5 mg Ra/cm
were initialy constructed with steel walls with
high emission of beta rays (Perez 1992).
Replacement steel walls by iridioplatium walls
which absorbed the beta rays responsible for
the painful necrosis allowed to improve the
tolerance of the intersitial irradiation. Single or
double plane platinum filtered radium needle
implants which delivere to 60 Gy during five to
seven days were used. According to Ellis
(1949), 18 % of patients treated by radium were
free of disease 5 years after treatment. Cade
and Lederman (1950) recommended
implantation of 6 cm long, low-intensity (0.66 -2
mg radium per needle) needles for unresectable
vulvar cancer. Four of 12 patients treated in this
way remained free of tumor relapse with follow
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up from 4 to 10 years. Tod and Paterson (1948)
used single or doubleplane radium needle
implants often with crossing sources instead of
teletherapy for vulvar neoplasms if surgery was
not possible. For the entire group of 116
patients treated by them between 1932-1941,
21% were free of disease five years after
treatment (33% of early cases and 14% of late
cases). The inguinal lymph nodes were
sometimes implanted by them, but the results of
treatment were extremely poor and surgical
extirpation or external beam irradiation was
recommended. Slevin and Pointon (1989)
obtained a 40% local control rate and a 26%
crude five year survival rate in 58 patients with
advanced vulvar lesions. There was a
suggestion that better local control was
observed in patients weith tumors 4 cm or less
in diameter. Minor radionecrosis appeared in
nine cases. Rutledge (1965) suggested the use
of radium needles in the place of incomplete
excision of vulvar lesions. In his opinion the
tolerance of radium implants were better than
external radiation. Occasionaly radium implants
alone were used in the treatment early lesions
mainly in patients with poor operative risk.
Radium interstitial irradiation was regarded as
equally effective as ·surgical procedure for early
lesions. But the complication rate, particulary
radionecrosis was high and limited this
procedure in daily practice. In Ellies series thirty
three cases of necrosis were observed in 103
patients who received same form of radiation
(Ellis 1949).
The most authors reported the use of
platinum filtered radium needle implants for
unresectable primary or recurrent disease. In 21
patients with recurrent carcinoma of the vulva
treated by brachytherapy combined with
external irradiation Prempree and Amornman
(1984) foundt that 6 with tumor limited to the
perineum, vagina or both had tumor control and
survived 5 years. However, none of the patients
with extensive recurrences survived, although
some had transied tumor regression.
Additionally to brachytherapy, the use of
external irradiation (40 - 50 Gy/g) was
recommended for all advanced lesions, all
postoperative recurrences and all cases with
inguinal lymph node metastases. The
brachytherapy doses were 20 - 30 Gy during
one to two days. Usually, radium implantations
were peformed in accordance with Paterson-
Parker rules. According to Prempree and
Amornmarn (1984), Factors responsible for the
succes of radiation therapy of the vulvar
carcinoma apper to include size and depth of
reccurence (5cm or less lesion has a high
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chance for cure); groin node (less than or equal
to 2 em has good prognosis ; perineal skin
involument (the smaller, the better); degree of
tumor necrosis (the smaller, the better) and
radiation dose (55 - 85 Gy).
Cesium needles with 0.66 and 0.33 mg
Ra/cm commonly used for interstitial implants, in
the treatment vulvar lesions were used very
rarely (cit. Erickson 1996). Radium and cesium
needles implantation techniques were limited by
the stock of varius lengths and strengths which
were available..The longest active lenght of
radium needle was 6 cm. Longer needles were
too brittle for insertion. Iridium 192 was available
in a much greater range of lengths and activites
and was much narrow in diameter. Free-hand or
template-guided techniques have been used to
perform insertion. The template-guided
procedure allow to get a more predictable
distribution of needles than possible with
freeOhand techniques. Iridium 192 has been
used increasingly since 1958 (Perez 1992).
Cuccia (1966) reported the use of iridium for
vulvar lession that exceeded the maximum
lenght of the radium needles available. Hollow
needles were inserted first and next manualy
afterloaded with irridium. Pohar et al (1995)
accumulated a large experience at the Centre
Alexis Vautrin in Nancy (in France). These
authors reported use of free-hand iridium
implantations in plastic tubes in 34 patients
treated between 1975-1993. Twenty one
patientswere treated becouse of primary tumor
when surgery was contraindicated and 13
patients were treated for recurrent disease.' If
tumor thickness was less than 1.5 cm interstitial
irradiation was used alone. If thickness cross
this value,external beam irradiation followed by
brachytherapy was recommended. The single-
double or tripple plane implants were performed
according to the Paris system rules. The
average brachytherapy dose was 60 Gy
prescribed to the reference isodose.
Locoregional recurrences developed in three of
21 patients treated for primary carcinoma of the
vulva and in eight of 13 patients treated for
recurrent disease at a median follow-up of 31
month. The toxicity of the treatment was low.
Authors concluded that brachytherapy may be
resonable alternative method to surgery,
particulary when surgical procedure is
contrindicated and for recurrent disease. Carlino
et al (1984) reported use perineal templates
(theSyed-Neblett template) through which steel
needles were inserted and next afterloaded with
Ir 192 combined .with or without surgery or
external beam irradiation. The best results were
achived when surgery and brachytherapy were
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jointed compared to brachytherapy with
teleradiotherapy (72% vs 25% free of disease at
five years). Martinez et al (1983) described the
use of iodine 125 or iridium 192 interstitial
implants in the treatment 35 patients with
perineal malignancies. Implantation was usually
performed to treat evident or microscopic
disease in conjuction with external beam pelvic
treatment with or without local excision. The
overall local control rate was 88%. 27 patients
are alive and free of disease from 37 to 76
minths. At Memorial Sloan Kettering, the use of
interstitial irradiation alone in the treatment of
the carcinoma of the vulva was advocated for
patients with small primary tumors who were
medically inoperable (Nori 1987). Brachytherapy
combined with external beam was
recommended for patients with large inoperable
or recurrentlesions if there was substantial
regression of disease with teletherapy. Dose
rates of 4.0 to 8.0 Gy/hr were recommended to
deliver a minimum 60 Gy when brachytherapy is
used alone or 30 - 40 Gy as a boost following
external beam doses of 40 to 50 Gy/tumor.
Perez et al (1993), Rush et al (1992)
recommended brachytherapy as a boost (10 -
20 Gy) to the tumor or excision site following
external beam irradiation with excellent tumor
control. Hockel and Muller (1991) have also
treated primary and recurrent vulvar lesions with
perineal template but used high-activity Ir 192.
The ability of brachutherapy using high activity
iridium 192 to control squamous cell carcinoma
of the vulva aws documented by Batterman
(1992).
There is common that interstitial
implantation was highly effective but highly
morbid method. The toxicity rate was higher in
patients with brachytherapy doses more than 60
Gy. Hoffman et al (1990) treated ten patients
with locally advanced cancer with brachytherapy
alone or combined with external beam
irradiation. The local control was obtained in 7
patients. They remain free of disease at a
median follow-up of 28 months. Radionecrosis
developed in six patients at a average time of
8.5 months after radiotherapy. Five of them
required wide excision and coverage with flaps.
CONCLUSION
Brachytherapy offers properly selected
patients an innovative alternative to radical
surgery with the excellent local control. The use
of intersitial irradiation as a boost in combination
with external beam irradiation has enabled a
reduction in the dose from teleradiotherapy,
causing less toxicity of the treatment with good
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macroscopic and microscopic control of
disease.
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